Orion has launched Vantas (histrelin) for the palliative treatment of advanced prostate cancer.

Vantas (histrelin) is a depot formulation of a luteinising-hormone releasing hormone (LHRH) analogue. Inserted subcutaneously into the upper arm, the implant delivers an average of 50 micrograms of histrelin acetate daily for 12 months. Histrelin inhibits LH secretion leading to a fall in circulating testosterone levels promoting tumour regression and symptom improvement.

Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely monitored for exacerbation of symptoms during the first few weeks after Vantas implantation.

View Vantas drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...